|Values are valid only on day of printing.|
Evaluation of suspected insulinoma characterized by hypoglycemia and increased plasma insulin concentration.
Detecting drugs that stimulate insulin secretion
If hypoglycemia is the result of 1 of these drugs, the test will detect the drug at physiologically significant concentrations in serum during an episode of hypoglycemia.
Drugs detected by this procedure are:
-The first-generation sulfonylureas-acetohexamide, chlorpropamide, tolazamide, and tolbutamide
-The second-generation sulfonylureas--glimepiride, glipizide, and glyburide
Drugs designed to make tissues more sensitive to insulin that do not induce hypoglycemia, such as pioglitazone, rosiglitazone, and troglitazone (recently withdrawn from the United States market) are not included in this screen test.
Drugs that lower blood glucose through mechanisms not related to stimulation of insulin secretion, such as acarbose, metformin, and miglitol are not included in this screen test.
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)